Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · IEX Real-Time Price · USD
1.660
+0.010 (0.61%)
Jul 22, 2024, 11:11 AM EDT - Market open
Regulus Therapeutics Employees
Regulus Therapeutics had 30 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
30
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,045,567
Market Cap
108.67M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Augmedix | 1,430 |
FibroGen | 486 |
Karyopharm Therapeutics | 325 |
I-Mab | 220 |
BrainsWay | 134 |
IO Biotech | 68 |
Zentek | 24 |
Coya Therapeutics | 8 |
RGLS News
- 13 days ago - Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - PRNewsWire
- 4 weeks ago - Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 6 weeks ago - Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes - PRNewsWire
- 2 months ago - Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer - PRNewsWire
- 2 months ago - Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates - PRNewsWire
- 2 months ago - Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - PRNewsWire
- 2 months ago - Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series - PRNewsWire
- 4 months ago - Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates - PRNewsWire